Dapagliflozin
Trade name Farxiga
Oral agent to treat type 2 diabetes
Approved for glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Approved as combination with metformin.extended-release, called Xigduo XR.
Inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney.
In clinical trials lowers HbA1c by 0.90 percentage points when added to metformin.
Heavy glycosuria can lead to rapid weight loss, tiredness, polyuria, and can lead to dehydration.
Glycosuria can also worsen the infections already associated with diabetes, such
as urinary tract infections and candidiasis.
Associated with hypotensive reactions.
Does not interfere with intestinal glucose absorption.
Among patient with heart failure and reduced for ejection fraction, the risk of worsening heart failure or death was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (McMurrayJ).
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and mildly reduced or preserved ejection fraction (DELIVER Trial Committees and investigators).